EISAI has presented new clinical data regarding treatment with lecanemab (Leqembi) amyloid-lowering therapy in adult patients with early Alzheimer's disease, demonstrating continued benefits over 48 months.
Participants taking lecanemab had delayed disease progression by 9.8 months compared to those in the untreated control group, and they were 32% less likely to have progressed to the next stage of the disease.
The company stated that the findings add to the growing evidence base demonstrating the potential benefits of lecanemab for eligible patients.
The Therapeutic Goods Administration (TGA) approved the medicine's registration in Sep last year (PD 26 Sep 2025), a move welcomed by dementia advocates.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Feb 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Feb 26
